This confirmed the profound sensitivity of BRCA1 mutant models (surviving fraction 50 concentration, SF50, for SUM149 = 0.01 μM and MDA-MB-436 SF50 = 0.0002 μM), the comparative olaparib resistance of TN models such as CAL51, MDA-MB-468, HS578T and MDA-MB-231 (SF50 = 1–27 μM) and the more significant resistance of the BT20 TN breast tumour cell line model, which did not reach SF50 within the concentration range 1 nM to 100 μM (Fig 1A and Supporting Information Table S3A). The gene discussed is BRCA1; the disease is breast neoplasm.